Enimmune Corporation (TPEX:6564)
16.50
-0.20 (-1.20%)
Jul 14, 2026, 12:34 PM CST
Enimmune Market Cap
Enimmune has a market cap or net worth of 1.19 billion as of July 14, 2026. Its market cap has increased by 2.48% in one year.
Market Cap
1.19B
Enterprise Value
1.14B
Revenue
48.19M
Ranking
n/a
PE Ratio
n/a
Stock Price
16.50
Market Cap Chart
Since September 18, 2018, Enimmune's market cap has decreased from 1.33B to 1.19B, a decrease of -10.40%. That is a compound annual growth rate of -1.39%.
| Date | Market Cap | % Change |
|---|---|---|
| Jul 14, 2026 | 1.19B | -19.90% |
| Dec 31, 2025 | 1.49B | -17.27% |
| Dec 31, 2024 | 1.80B | -27.21% |
| Dec 29, 2023 | 2.47B | -38.63% |
| Dec 30, 2022 | 4.02B | 69.85% |
| Dec 30, 2021 | 2.37B | -11.74% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 26, 2018 | Upgrade Pro | Upgrade Pro |
| Sep 18, 2018 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| GenMont Biotech Incorporation | 1.41B |
| Andros Pharmaceuticals Co.,Ltd | 1.41B |
| NeoCore Technology | 1.31B |
| Abnova (Taiwan) | 1.26B |
| BiOptic | 1.16B |
| LabTurbo Biotech | 1.11B |
| Lukas Biomedical | 1.07B |
| Bio Preventive Medicine | 1.06B |